(Total Views: 289)
Posted On: 12/18/2019 1:03:58 PM
Post# of 155792
I listened again to the section on MS....
Basically, they believe leronlimab may work in MS to prevent reoccurrences because of the mice data. They believe it actually may work better than what the mice model showed because leronlimab is very specific for human CCR5 and not mouse CCR5. They have already written a phase 2 protocol and it sounds like they will progress that direction and not purse a trial of leronlimab in a humanized mouse model.
They explained they had similar findings in the NASH. The first results of leronlimab in a NASH mouse model were good but they were great once they used a humanized model.
Basically, they believe leronlimab may work in MS to prevent reoccurrences because of the mice data. They believe it actually may work better than what the mice model showed because leronlimab is very specific for human CCR5 and not mouse CCR5. They have already written a phase 2 protocol and it sounds like they will progress that direction and not purse a trial of leronlimab in a humanized mouse model.
They explained they had similar findings in the NASH. The first results of leronlimab in a NASH mouse model were good but they were great once they used a humanized model.
(3)
(0)
